featured
Digoxin Use in Patients With Atrial Fibrillation and Adverse Cardiovascular Outcomes: A Retrospective Analysis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Risk for Death and Stroke Higher in Persistent vs Paroxysmal Atrial Fibrillation
- Rivaroxaban vs Warfarin in Patients With Non-Valvular Atrial Fibrillation
- Efficacy and Safety of Rivaroxaban vs Warfarin in Elderly Patients With AF
- Outcome of Antiarrhythmic Therapy in Anticoagulated Patients With Atrial Fibrillation Receiving Anticoagulation
- Management of Major Bleeding in Atrial Fibrillation With Rivaroxaban vs Warfarin
- Temporary Interruption of Rivaroxaban vs Warfarin in Patients With Nonvalvular Atrial Fibrillation
- Factors Associated With Major Bleeding Events in AFib Patients Treated With Rivaroxaban
- Ischaemic Cardiac Outcomes in Patients With Atrial Fibrillation Treated With Vitamin K Antagonism or Factor Xa Inhibition: Results From the ROCKET AF Trial
- Rivaroxaban Provides Adequate Protection for Cardioversion and AF Ablation
- Rivaroxaban Appears Safe, Effective in Patients With Heart Failure and Afib
- Explanation Proposed for Stroke Risk During Rivaroxaban Transition
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Digoxin Use in Patients With Atrial Fibrillation and Adverse Cardiovascular Outcomes: A Retrospective Analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Lancet 2015 Mar 05;[EPub Ahead of Print], JB Washam, SR Stevens, Y Lokhnygina, JL Halperin, G Breithardt, DE Singer, KW Mahaffey, GJ Hankey, SD Berkowitz, CC Nessel, KA Fox, RM Califf, JP Piccini, MR PatelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.